

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Homocysteine: The Amino Acid Toxin.

Dinesh Prakash Upadhyay and Laxmikant Gupta*

Department of Chemistry, M. S. J. College, Bharatpur (Raj.) INDIA.

ABSTRACT

Homocysteine is an amino acid formed by metabolism of essential amino acid, methionine. Its role in body functionality has been relatively underestimated in comparison to cholesterol. New scenario has come up in regards to critical risks of Homocysteine. The elevated level of Homocysteine in blood arises due to its improper depletion from the body and poses high risk factor for vascular diseases, stroke, complications of diabetes and improper functioning of neurotransmitters. The Homocysteine level can be measured by simple blood test. Folic acid, vitamin B12 and B6 can substantially reduce the risk of elevated Homocysteine levels. **Key words**: Homocysteine, amino acid, toxin.

*Corresponding author

5(1)



INTRODUCTION

Amino acids are biologically important organic compound which are the building blocks of the protein. They contain amino and carboxylic as main functional groups. For proper body functioning twenty amino acids are required. Out of these nine are essentials i.e. the human body cannot synthesize and external supplement is needed for them.

The nine essential amino acids are histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. Out of these essential amino acids methionine is sulphur containing i.e. it possess sulphur besides carbon, nitrogen, oxygen and hydrogen. In the class of sulphur containing amino acids cysteine is also there but it is non- essential amino acid.

Homocysteine is an amino acid which is formed in the body from the metabolism of the methionine. Nowadays, there has been upsurge of concern regarding toxicity of the elevated levels of Homocysteine and in comparison to cholesterol its role in vascular diseases has been under estimated. In this paper, we have summarised some of emerging scenario regarding Homocysteine and its toxic effects.

Structure of Homocysteine:

The structure of Homocysteine quite resembles to structure of cysteine (Figure.1)



Figure 1: Cysteine amino acid

Homocysteine (Figure 2) is a homologue of cysteine and contains an additional methylene group than cysteine.



Figure 2: Homocysteine molecule

5(1)

ISSN: 0975-8585



Bodily formation and metabolism of Homocysteine:

In human body, Homocysteine is formed by the metabolism of methionine molecule (Figure 3).



Figure 3: Methionine amino acid

The essential amino acid methionine contains one methyl group attached to the sulphur atom. This methyl group gets removed during metabolism of methionine. A schematic presentation of methionine metabolism and its regeneration is given in Figure 4:



Figure 4: Metabolism and regeneration of methionine, and formation of Homocysteine

In this pathway, the formation of S-adenosylmethionine (SAM) transfers a methyl group to any methyl acceptor molecule (such as neurotransmitter, protein, DNA etc.) and forms Sadenosylhomocysteine (SAH) which is converted to Homocysteine.

Homocysteine re-methylation occurs via methyl-tetrahydrofolate (MTHF) which is the active form of folic acid and is converted back to methionine molecule. The concentration of Homocysteine formed by the metabolism of methionine gets depleted by its reverse conversion to methionine viz. with the help of vitamin B6, B12 and folic acid.

Risks of Homocysteine:

A normal Homocysteine level is between 4.4 and 10.9 micromoles per litre of blood. The concentration of Homocysteine in male-female age is presented in Table 1.



Sex	Age	Lower limit	Upper limit	Unit	Elevated
Female	12–19 years	3.3	7.2	µmol/L	> 10.4 µmol/L
		45	100	µg/dL	or
	>60 years	4.9	11.6	µmol/L	> 140 µg/dL
		66	160	µg/dL	
Male	12–19 years	4.3	9.9	µmol/L	> 11.4 µmol/L
		60	130	µg/dL	or
	>60 years	5.9	15.3	µmol/L	> 150 µg/dL
		80	210	µg/dL	

Table1: Male-Female Homocysteine levels at different age[1]

Homocysteine levels are typically higher in men than women, and increase with age.

Homocysteine, when present in high concentration promotes mortality, and causes risk of cardiovascular disease[2,3] (CVD), stroke, complications of diabetes, improper functioning of neurotransmitters, Alzheimer's disease, birth defects, recurrent pregnancy loss, and many more disorders. A reference to dependency of mortality rate[4] on Homocysteine concentration level is given in Table 2.

Table2: Mortality ratio dependency on Homocysteine levels

Concentration of Homocysteine	Mortality Ratio
5.1-8.9 μmole/lit.	1
9.0-11.9 μmole/lit.	1.33
12.0-14.9 μmole/lit.	2.02
15.0-19.9 μmole/lit.	2.48
>20 µmole/lit.	3.56

A reference to disease risk[5] due to elevated Homocysteine levels has been summarised in Table 3.

Name of disease	Homocysteine level
Coronary artery disease(CAD)	>6.5 µmole/lit.
Kidney Disorders	Thirty times higher risk than CAD
Acute coronary syndrome	>12.0 μmole/lit.
Stroke ⁷	>14.24 µmole/lit.
Diabetes	>5 μmole/lit.
Hyperhomocystenemia	>14µmole/lit.
Dementia	>14 µmole/lit.

Table3: Disease risk due to elevated Homocysteine levels[6]

High Homocysteine level has high risk factor in comparison to "good" HDL cholesterol due to depression of cardiac copper levels. The copper levels have a protective effect on the heart against oxidative damage. That is why Homocysteine increases the risk of arteriosclerosis [8] and have more damaging effect than cholesterol.



Factors affecting Homocysteine level:

There are several factors affecting Homocysteine level, some of them are presented in Table 4.

Diet	Low consumption of foods and vegetables	
	Low intake of folic acid, Vitamin B6, B12 and other multivitamins.	
	High intake of methionine containing proteins	
Life Style	Alcohol consumption,	
	High consumption of coffee	
	Smoking	
Disease or inherited	nherited Diabetes, Hyperthyroidism, Psoriasis, Rheumatoid arthritis,	
causes	Certain malignancies, renal failure, Malabsorption syndrome	
	Mehtionine synthase deficiencies, Cystathionine β - synthase deficiencies	
General	Male gender, increased age, menopause	
Drugs increasing	Estrogens containing oral contraceptives	
Homocysteine level	Some antiepileptic drugs	
	Niacin, Sulfasalazine, Diuretic therapy etc.	

Table 4: Factors affecting Homocysteine levels

Prevention of elevated Homocysteine level:

Elevated Homocysteine level is a risk factors for several diseases or initiation of diseases. Prevention provides a cheap way to cure. The lowering of Homocysteine can be achieved by a change in life style, regular check up, and intake of diet full of green vegetables, beans and multivitamins. The vitamins which are especially useful in controlling the Homocysteine levels are Folic acid, Vitamin B6 and Vitamin B12. These vitamins help in reverse conversion of Homocysteine into methionine. Adequate amounts of vitamin B6, B12, and folic acid intake is required for keeping Homocysteine at levels associated with lower rates of the diseases. Supplementation with one or more of these vitamins can lower plasma levels of Homocysteine, regardless of the cause of the elevation. Although the doses of these vitamin has not been clearly established yet, but 0.3-1 mg Folic acid, 2-25 mg Vitamin B6 and 0.01-0.1 mg Vitamin B12 may serve the purpose. Higher doses may be required in patients with other complaints.

CONCLUSION

Homocysteine is an amino acid toxin, formed in the body from metabolism of methionine. Elevated Homocysteine levels promote mortality, and cause risks of cardiovascular disease (CVD), stroke, complications of diabetes, improper functioning of neurotransmitters, Alzheimer's disease, birth defects, recurrent pregnancy loss, and many more disorders. The risks of initiation of vascular diseases by Homocysteine may be more prominent than cholesterol. Its levels should be watched carefully. Folic acid, vitamin B6 and vitamin B12 are helpful in lowering the blood Homocysteine levels.



REFERENCES

- [1] Wolters M, Hermann S, Hahn A. Am J Clin Nutr 2003; 78(4): 765-772.
- [2] Carmel R, Jacobsen D. Homocysteine in Health and Disease. Cambridge University Press; UK Press; 2001.
- [3] Jacobsen DW. Clin Chem 1998; 44: 1833-1843.
- [4] Vollset SE, Refsum H, et. al. Am J Clin Nutr 2001; 74(1): 130-136.
- [5] Herrmann W. Clin Chem Lab Med 2001; 39(8): 666-674.
- [6] Hoogeveen EK, et al. Circulation 2000; 101(13): 1506-1511.
- [7] Abbate R, Sofi F, Brogi D, Marcucci R. Neurol Sci 2003; 24(suppl 1): S11-S12.
- [8] Virdis A, et al. J Nephrol 2002; 15: 414-421.

5(1)